LSBio, Seattle, has acquired Redcar, UK-based Absolute Antibody and its sister company Kerafast. Terms of the transaction were not disclosed.
LSBio provides IHC-validated reagent antibodies and services to the global community of academic, pharmaceutical, and biotech researchers. The company has built a catalog of more than 750,000 reagent antibodies, assay kits, proteins, and biochemicals, and its acquisition of Absolute Antibody and Kerafast further expands its product portfolio by adding a range of unique reagents and antibody services.
Absolute Antibody specializes in recombinant antibody technology, offering antibody sequencing, engineering and recombinant production as custom services, as well as a unique catalog of recombinant antibodies and Fc Fusion proteins, engineered into new and useful formats. In 2018, Absolute Antibody merged with Kerafast, a Boston-based company that facilitates access to unique laboratory-made reagents, to further the availability of recombinant antibodies. The new acquisition combines a strong recombinant antibody portfolio with LSBio’s expertise in application-specific validation to make sequence-defined, reproducible antibodies more widely available for IHC and other key research applications, according to the company.
“We are very excited to add Absolute Antibody and Kerafast into the LSBio family of companies,” says Heather Holemon, PhD, CEO of LSBio. “It provides an opportunity to offer more to our customers by adding their recombinant antibody production and engineering capabilities as well as their highly complementary product portfolio. This transaction aligns with our goal of providing researchers access to what they are asking for as far as superior consistency and better validation.”
“We are delighted to be joining forces with the LSBio team,” says Nicholas Hutchings, DPhil, founder and CEO of Absolute Antibody. “Absolute Antibody was founded with a vision to make engineered recombinant antibodies accessible to all, and we have grown rapidly as the demand for recombinant antibody technology has increased. That vision remains and working with LSBio enables us to continue growing both the recombinant antibody catalog and our custom services, while still delivering the highest level of product quality and customer satisfaction.”
The acquisition marks the latest investment by LSBio to rapidly build its product portfolio. In 2019, LSBio acquired both Nordic-MUbio and Everest Biotech to strengthen the company’s offering of proprietary monoclonal and polyclonal antibodies. All LSBio companies currently retain their independent names, websites, and employees, with the entire family of companies owned by St. Louis-based private equity firm Thompson Street Capital Partners.
For more information, visit LSBio and Absolute Antibody.
Featured image: A laboratory within the Absolute Antibody manufacturing facility.
